Real-world analysis of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients

Sodium-glucose cotransporter-2 (SGLT2) inhibitors decrease blood sugar ranges and have extra helpful results on kidney and coronary heart well being for people with and with out diabetes, however little is thought concerning the security and efficacy of those medicines in kidney transplant recipients. Analysis that examined this will likely be offered at ASN Kidney Week 2023 November 1–5.

For the research, investigators analyzed the electronic medical records of three,450 grownup kidney transplant recipients handled with SGLT2 inhibitors who have been matched to three,450 related sufferers who didn’t obtain SGLT2 inhibitors, utilizing a statistical method known as propensity matching adjusted for demographic information, baseline coronary heart illness and blood check.

Kidney transplant sufferers handled with SGLT2 inhibitors have been 59%, 64%, 33%, and 40% much less more likely to expertise kidney transplant rejection, kidney transplant failure, main adversarial cardiac occasions, and mortality, respectively, over 3 years. They have been additionally 44% much less more likely to expertise urinary tract infections.

“So far, all main SGLT2 inhibitor research have excluded kidney transplant patients. This research was the biggest observational research demonstrating the advantages of SGLT2 inhibitors in sufferers with kidney transplants,” mentioned corresponding creator Nageen, Anwar, MD, of the Liverpool College Hospitals NHS Basis Belief.

“This research is an enormous step in the direction of qualifying transplant sufferers to profit from the various constructive results of SGLT2 inhibitor use and units the priority for a randomized controlled trial to judge the long-term kidney and cardiovascular outcomes of SGLT2 inhibitor remedy in kidney transplant sufferers.”